Anti-Beta2 Glycoprotein I IgG is a specific class of autoantibodies directed against beta-2 glycoprotein I (β2GPI), a plasma protein that plays a critical role in the regulation of coagulation. The presence of these autoantibodies is clinically significant, particularly in autoimmune disorders such as Antiphospholipid Syndrome (APS), where they contribute to a hypercoagulable state. APS, characterized by thrombosis and pregnancy morbidity, is often associated with the presence of anti-β2GPI IgG, along with other antiphospholipid antibodies like lupus anticoagulant and anti-cardiolipin antibodies. The anti-β2GPI IgG antibodies interact with β2GPI, altering its normal function in coagulation control, leading to an increased risk of clot formation in both arteries and veins. Elevated levels of these antibodies can be detected through serological assays and are considered a major criterion for the diagnosis of APS. The persistence of high levels of anti-β2GPI IgG over time is often correlated with a greater risk of thrombotic events. Their detection is not only crucial for diagnosing APS but also for assessing the risk of recurrent thrombosis and guiding long-term management strategies, including anticoagulation therapy. The study and understanding of anti-β2GPI IgG antibodies have profound implications in the fields of rheumatology, hematology, and obstetrics, particularly in managing patients with autoimmune disorders and thrombotic tendencies.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.